Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-01-23

Clinical Trial Update: Long Term Efficacy, Safety and Immunogenicity of Enerceptan in Rheumatoid Arthritis ( GEMENE002 ) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on Enerceptan for rheumatoid arthritis, focusing on long-term efficacy, safety, and immunogenicity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Enerceptan

Snippet

Sponsor: Gema Biotech S.A. | Conditions: Rheumatoid Arthritis | Phase 3 | Status: UNKNOWN